Access cutting-edge thrombotic thrombocytopenic purpura treatment through this clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Oklahoma City location
Preparing your pre-screening questions…
Access thrombotic thrombocytopenic purpura specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related thrombotic thrombocytopenic purpura treatment provided free
Check if you qualify for this thrombotic thrombocytopenic purpura clinical trial in Oklahoma City, OK
No-Cost Study Care
Local to Oklahoma City
Convenient for OK residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations. Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections.
Sponsor: Insel Gruppe AG, University Hospital Bern
Yes, this clinical trial (NCT01257269) has an active research site in Oklahoma City, OK that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for thrombotic thrombocytopenic purpura treatment options in Oklahoma City, OK, this clinical trial (NCT01257269) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Oklahoma City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced thrombotic thrombocytopenic purpura specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all thrombotic thrombocytopenic purpura clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Oklahoma City — not just this study.
Browse Pulmonary Embolism Trials in Oklahoma City →